Rosuvastatin for Primary Prevention in Older Persons With Elevated C-Reactive Protein and Low to Average Low-Density Lipoprotein Cholesterol Levels: Exploratory Analysis of a Randomized Trial

Division of Preventive Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts 02215, USA.
Annals of internal medicine (Impact Factor: 17.81). 04/2010; 152(8):488-96, W174. DOI: 10.1059/0003-4819-152-8-201004200-00005
Source: PubMed


Randomized data on statins for primary prevention in older persons are limited, and the relative hazard of cardiovascular disease associated with an elevated cholesterol level weakens with advancing age.
To assess the efficacy and safety of rosuvastatin in persons 70 years or older.
Secondary analysis of JUPITER (Justification for the Use of statins in Prevention: an Intervention Trial Evaluating Rosuvastatin), a randomized, double-blind, placebo-controlled trial.
1315 sites in 26 countries randomly assigned participants in JUPITER.
Among the 17 802 participants randomly assigned with low-density lipoprotein (LDL) cholesterol levels less than 3.37 mmol/L (<130 mg/dL) and high-sensitivity C-reactive protein levels of 2.0 mg/L or more without cardiovascular disease, 5695 were 70 years or older.
Participants were randomly assigned in a 1:1 ratio to receive 20 mg of rosuvastatin daily or placebo.
The primary end point was the occurrence of a first cardiovascular event (myocardial infarction, stroke, arterial revascularization, hospitalization for unstable angina, or death from cardiovascular causes).
The 32% of trial participants 70 years or older accrued 49% (n = 194) of the 393 confirmed primary end points. The rates of the primary end point in this age group were 1.22 and 1.99 per 100 person-years of follow-up in the rosuvastatin and placebo groups, respectively (hazard ratio, 0.61 [95% CI, 0.46 to 0.82]; P < 0.001). Corresponding rates of all-cause mortality in this age group were 1.63 and 2.04 (hazard ratio, 0.80 [CI, 0.62 to 1.04]; P = 0.090). Although no significant heterogeneity was found in treatment effects by age, absolute reductions in event rates associated with rosuvastatin were greater in older persons. The relative rate of any serious adverse event among older persons in the rosuvastatin versus placebo group was 1.05 (CI, 0.93 to 1.17).
Effect estimates from this exploratory analysis with age cut-point chosen after trial completion should be viewed in the context of the overall trial results.
In apparently healthy older persons without hyperlipidemia but with elevated high-sensitivity C-reactive protein levels, rosuvastatin reduces the incidence of major cardiovascular events.


Available from: James Shepherd, Jan 09, 2014
  • Source
    • "Chiral drugs contain at least one chiral center, resulting in 2n−1 pairs of enantiomers. Widely used chiral drugs, such as rosuvastatin, duloxetine and salbutamol, play an important role in treating human diseases1,2,3. In the environment of living systems, specific binding between molecules (eg, enzymes, receptors, transporters, and DNA) is required for their medicinal effect. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Chiral drugs show distinct biochemical and pharmacological behaviors in the human body. The binding of chiral drugs to plasma proteins usually exhibits stereoselectivity, which has a far-reaching influence on their pharmacological activities and pharmacokinetic profiles. In this review, the stereoselective binding of chiral drugs to human serum albumin (HSA), α1-acid glycoprotein (AGP) and lipoprotein, three most important proteins in human plasma, are detailed. Furthermore, the application of AGP variants and recombinant fragments of HSA for studying enantiomer binding properties is also discussed. Apart from the stereoselectivity of enantiomer-protein binding, enantiomer-enantiomer interactions that may induce allosteric effects are also described. Additionally, the techniques and methods used to determine drug-protein binding parameters are briefly reviewed.
    Acta Pharmacologica Sinica 07/2013; 34(8). DOI:10.1038/aps.2013.78 · 2.91 Impact Factor

  • Current Cardiovascular Risk Reports 11/2010; 4(6):399-401. DOI:10.1007/s12170-010-0126-4
  • [Show abstract] [Hide abstract]
    ABSTRACT: Cardiovascular disease remains the leading cause of death in the United States, with the greatest burden borne by adults above 65 years of age. HMG-CoA-reductase inhibitors, or statins, have been demonstrated to greatly reduce morbidity and mortality in patients with established cardiovascular disease, yet their rates of utilization in older adults remain relatively low. In addition, few trials have specifically analyzed the efficacy of statins in older patients. This review summarizes the data relevant to the use of statins for the primary and secondary prevention of cardiovascular disease in older adults as well as some of the controversies regarding possible links between statins and cognitive impairment or diabetes.
    Current Cardiovascular Risk Reports 10/2012; 6(5). DOI:10.1007/s12170-012-0256-y
Show more